DALLAS, Nov. 4, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Novavax Inc. (Nasdaq:NVAX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Novavax Inc. (Nasdaq:NVAX) should be of particular interest to other biotechnology companies: Novartis AG (NYSE:NVS), Merck & Co. Inc. (NYSE:MRK) and Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA).
It is available at: http://www.investorsoup.com/lp/NVAX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Novavax Inc. (NVAX) is a clinical-stage biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon preventive options for a range of infectious diseases. These vaccines leverage its virus-like particle (VLP) platform technology coupled with a disposable production technology. The Company's product targets include vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, Varicella Zoster, which causes shingles, and respiratory syncytial virus (RSV).
Message Board Search for NVAX: http://www.boardcentral.com/boards/NVAX
In the report, the analyst notes:
"Revenues for the three months ended June 30, 2009, were $29,000 as compared to $342,000 for the three months ended June 30, 2008, a decrease of $313,000, or 92%. The decrease in revenue from the comparable period in 2008 is due to lower contract research and development revenue. Contract research and development revenue is comprised of revenue from government and commercial research and development contracts and for the three months ended June 30, 2008 was comprised of revenue from two National Institutes of Health ('NIH') contracts, of which one of these ended in the first quarter of 2009.
"NVAX announced last week that CPL Biologicals Pvt. Ltd., the new joint venture between Cadila Pharmaceuticals in India, has begun construction of a state-of-the-art manufacturing facility that will be used to produce pandemic and seasonal influenza vaccines. CPL Biologicals will utilize NVAX's virus-like particle (VLP) vaccine technology to produce commercial-scale quantities of VLP-based influenza vaccines using NVAX's innovative disposable manufacturing solution."
To read the entire report visit: http://www.investorsoup.com/lp/NVAX
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.